BioAtla, Inc. Common Stock
BCAB Real Time Price USDRecent trades of BCAB by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by BCAB's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
BCAB Revenue by Segment or Geography
New patents grants
-
Patent Title: Conditionally active biological proteins Oct. 08, 2024
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts May. 07, 2024
-
Patent Title: Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof Feb. 13, 2024
-
Patent Title: Anti-ror2 antibodies, antibody fragments, their immunoconjucates and uses thereof Jan. 23, 2024
-
Patent Title: Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereof Dec. 26, 2023
-
Patent Title: Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof Dec. 05, 2023
-
Patent Title: Conditionally active polypeptides and methods of generating them Oct. 03, 2023
-
Patent Title: Mirac proteins Aug. 08, 2023
-
Patent Title: Methods of protein evolution May. 02, 2023
-
Patent Title: Conditionally active chimeric antigen receptors for modified t-cells Feb. 21, 2023
-
Patent Title: Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof Jan. 03, 2023
-
Patent Title: Conditionally active polypeptides Oct. 18, 2022
-
Patent Title: Comprehensive monoclonal antibody generation Jul. 26, 2022
-
Patent Title: Express humanization of antibodies Jul. 26, 2022
-
Patent Title: Proteins targeting orthologs Apr. 05, 2022
-
Patent Title: Conditionally active polypeptides and methods of generating them Mar. 22, 2022
-
Patent Title: Conditionally active biological proteins Feb. 22, 2022
-
Patent Title: Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof Feb. 22, 2022
-
Patent Title: Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof Oct. 19, 2021
-
Patent Title: Conditionally active chimeric antigen receptors for modified t-cells Sep. 07, 2021
-
Patent Title: Modified antibody regions and uses thereof Mar. 23, 2021
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Feb. 16, 2021
-
Patent Title: Methods of protein evolution Nov. 10, 2020
-
Patent Title: Diagnostics using conditionally active antibodies Jun. 30, 2020
-
Patent Title: Multi-specific monoclonal antibodies Jun. 30, 2020
-
Patent Title: Comprehensive monoclonal antibody generation Jun. 02, 2020
-
Patent Title: Express humanization of antibodies Feb. 18, 2020
-
Patent Title: Discovering and producing conditionally active biologic proteins in the same eukaryotic cell production hosts Dec. 24, 2019
-
Patent Title: Conditionally active biological proteins Jun. 25, 2019
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Oct. 23, 2018
-
Patent Title: Methods of protein evolution Oct. 23, 2018
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Aug. 14, 2018
-
Patent Title: Mirac proteins Jun. 12, 2018
-
Patent Title: Mirac proteins May. 29, 2018
-
Patent Title: Multi-specific monoclonal antibodies May. 15, 2018
-
Patent Title: Anti-cd22 antibodies Jan. 02, 2018
-
Patent Title: Mirac proteins May. 02, 2017
-
Patent Title: Mirac proteins May. 02, 2017
-
Patent Title: Mirac proteins Oct. 11, 2016
-
Patent Title: Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts Oct. 14, 2014
-
Patent Title: Mirac proteins Apr. 29, 2014
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to BCAB
Recent picks made for BCAB stock on CNBC
ETFs with the largest estimated holdings in BCAB
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $BCAB stock a Buy, Sell, or Hold?
- What is the price target for $BCAB stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $BCAB stock?
- Who owns the most shares of $BCAB stock?
- What funds own $BCAB stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view BCAB Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.